WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Teladoc Health
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Medical
Debiopharm | January 18, 2021
Debiopharm , a Swiss biopharmaceutical organization, reported the principal patient dosed in a investigator-initiated, randomized phase II, open-label clinical trial for its antiviral alisporivir (Debio 025). The examination will be led by the AP-HP to assess the adequacy and wellbeing of the cyclophilin inhibitor in the therapy of beginning phase, hospitalized COVID-19 patients who don't need clinical ventilation and have not shown indications of intense respiratory distress syndrome. The e...
Cell and Gene Therapy, AI
Businesswire | June 05, 2023
BenevolentAI, a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712. BEN-34712 is an oral, potent and selective brain penetrant RARɑβ (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies. Impaired retinoic acid signalling has bee...
Industrial Impact
Adaptive Biotechnologies | February 19, 2022
Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, presented data on T-cell receptor (TCR) sequences associated with Crohn’s disease (CD) during an oral presentation today at the 17th Congress of European Crohn’s and Colitis Organisation (ECCO) being held virtually February 16-19. The study identified and characterized TCR sequences associ...
Ebanga | December 29, 2020
Ridgeback Biotherapeutics LP ("Ridgeback"), a biotechnology organization experienced in antiviral drug improvement, reported today that the U.S. Food and Drug Administration ("FDA") approved EbangaTM for the treatment of Ebola. Ebanga is presently affirmed for treatment of disease brought about by Zaire ebolavirus in grown-up and pediatric patients. Ebanga is the only FDA endorsed, single infusion Ebola treatment which is accessible in a lyophilized structure.<...
Video
Medical, Industry Outlook
Whitepaper
Cell and Gene Therapy
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE